{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:42:46Z","timestamp":1792568566743,"version":"4.5.0"},"reference-count":116,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"L\u00e9on Fredericq Foundation"},{"name":"Fonds de la Recherche Scientifique \u2013 FNRS"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"DOI":"10.1080\/13543776.2026.2748595","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:03:44Z","timestamp":1791896624000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Positive allosteric modulators of AMPA receptors: advances and emerging trends"],"prefix":"10.1080","author":[{"given":"Thomas","family":"Colson","sequence":"first","affiliation":[{"name":"University of Li\u00e8ge","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Pirotte","sequence":"additional","affiliation":[{"name":"University of Li\u00e8ge","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Francotte","sequence":"additional","affiliation":[{"name":"University of Li\u00e8ge","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488906778773661"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2013.770840"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000131"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08624"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.5c05172"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01662"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.116.107599"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.109.002451"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1699275"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi8015907"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00424\u2013010\u20130809\u20131"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn725"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/40639"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00714"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13111609"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2008.01.011"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2003.054320"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/40645"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408269102"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0905570106"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56027-1"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.119.118554"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10178"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-02913-4"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1665997"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13696"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986710792927840"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136450"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006\u20138993(03)02357\u20136"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12100"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/JRLCR.S51475"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210\u2013200620030\u201300001"},{"key":"e_1_3_5_35_1","unstructured":"National Institute of Neurological Disorders and Stroke (NINDS). Tolerability and primary efficacy of CX516 in Alzheimer\u2019s disease [clinical trial registration] [internet]. Clinical trial registration no: NCT00001662. Available on: clinicaltrials.gov; 2008 [cited 2026 feb 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00001662"},{"issue":"8","key":"e_1_3_5_36_1","first-page":"814","article-title":"CX-516 (Cortex Pharmaceuticals inc)","volume":"2","author":"Danysz W","year":"1999","unstructured":"Danysz W. CX-516 (Cortex Pharmaceuticals inc). Drugs Invest Drugs J. 1999;2(8):814\u2013822.","journal-title":"Drugs Invest Drugs J"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2567\u201305.2005"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010056"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026616666160627114507"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119872198"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174742"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/09727531231185991"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511-11.2.56"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945007780618490"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1532877"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.040360"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2021.103814"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008766"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31819faa2a"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.194"},{"key":"e_1_3_5_51_1","unstructured":"Read 6 Min. BioSpace [Internet]. Cortex pharmaceuticals Inc.\u2019s AMPAKINE compound CX717 achieves primary endpoints in second phase IIa respiratory depression study in Germany. 2008 [cited 2026 feb 23]. Available from: https:\/\/www.biospace.com\/cortex-pharmaceuticals-inc-s-ampakine-compound-cx717-achieves-primary-endpoints-in-second-phase-iia-respiratory-depression-study-in-germany"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2014\u20130374OC"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00105"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00752.2012"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177317"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178047"},{"key":"e_1_3_5_57_1","unstructured":"ctv.veeva.com [Internet]. CX717 in the treatment of adult ADHD. [cited 2026 feb 23]. Available from: https:\/\/ctv.veeva.com\/study\/cx717-in-the-treatment-of-adult-adhd"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318291079c"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1475"},{"key":"e_1_3_5_60_1","unstructured":"RespireRx Pharmaceuticals Inc. [cited 2026 feb 25]. Available from: https:\/\/www.respirerx.com\/development\/cx1739.html"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184429"},{"key":"e_1_3_5_62_1","unstructured":"Ozmosi | S-47445 Drug Profile [Internet]. [cited 2026 feb 25]. Available from: https:\/\/pryzm.ozmosi.com\/product\/24842"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00462"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.04.005"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2024.2401312"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112458728"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115221"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.5b00318"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.06.008"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.13.7053"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2005.103812"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.1c00255"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116036"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6c00014"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112124"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.08.176"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2013021\u201393888\u20130"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02148-w"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061389"},{"key":"e_1_3_5_80_1","unstructured":"Drug Hunter [Internet]. TAK-653. [cited 2026 feb 24]. Available from: https:\/\/drughunter.com\/molecule\/tak-653"},{"key":"e_1_3_5_81_1","unstructured":"Neurocrine Biosciences. A randomized double-blind placebo-controlled study to assess the efficacy and safety of NBI-1065845 as adjunctive treatment in subjects with major depressive disorder (MDD) [clinical trial registration] [internet]. Clinical trial registration no: NCT06786624. Available on: clinicaltrials.gov; 2025 [cited 2026 feb 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06786624"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14713"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.204735"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401274b"},{"key":"e_1_3_5_85_1","unstructured":"Biogen. A randomized double-blind placebo controlled sponsor open parallel group phase 1b study to examine the safety tolerability and pharmacokinetics of multiple ascending doses of pf-04958242 in subjects with stable schizophrenia [clinical trial registration] [Internet]. Clinical trial registration no: NCT02332798. Available on: clinicaltrials.gov; 2021 [cited 2026 feb 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02332798"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2024.1405510"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2010.03.039"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01347-1"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202154543"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhad299"},{"key":"e_1_3_5_91_1","unstructured":"Zhou J Chen H Johnson KM et al. Bivalent Ampa Receptor Positive Allosteric Modulators [Internet]. US2015057248 (A1). 2015 [cited 2026 mar 13]. Available from: https:\/\/worldwide.espacenet.com\/publicationDetails\/biblio?FT=D&date=20150226&DB=&locale=fr_EP&CC=US&NR=2015057248A1&KC=A1&ND=4"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27238252"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1039\/c9md00262f"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200554"},{"key":"e_1_3_5_95_1","unstructured":"Neurocrine Biosciences. A randomized double-blind placebo-controlled 3-period crossover study followed by 1 open-label comparator period to evaluate central nervous system pharmacodynamic activity of TAK-653 in healthy volunteers using transcranial magnetic stimulation [clinical trial registration] [internet]. Clinical trial registration no: NCT03792672. Available on: clinicaltrials.gov; 2021 [cited 2026 feb 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03792672"},{"key":"e_1_3_5_96_1","unstructured":"Neurocrine Biosciences. A phase 1 randomized double-blind placebo-controlled safety tolerability and pharmacokinetic study of escalating single and multiple doses of TAK-653 in healthy subjects [clinical trial registration] [internet]. Clinical trial registration no: NCT02561156. Available on: clinicaltrials.gov; 2021 [cited 2026 feb 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02561156"},{"key":"e_1_3_5_97_1","unstructured":"Hasui T Nakamura S Mikami S et al. Heterocyclic compounds [internet]. US11447488B2. 2022 [cited 2026 aug 13]. Available from: https:\/\/patents.google.com\/patent\/US11447488B2\/en"},{"key":"e_1_3_5_98_1","unstructured":"Millennium Pharmaceuticals Inc. A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of TAK-653 in the treatment of subjects with treatment-resistant depression [clinical trial registration] [internet]. Clinical trial registration no: NCT03312894. Available on: clinicaltrials.gov; 2018 [cited 2026 feb 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03312894"},{"key":"e_1_3_5_99_1","unstructured":"Giblin GM MacPherson DT Williams M et al. Novel salts [Internet]. US20200255438A1. 2020 [cited 2026 aug 13]. Available from: https:\/\/patents.google.com\/patent\/US20200255438A1\/en?oq=US20200255438A1"},{"key":"e_1_3_5_100_1","unstructured":"Ward S Beswick P Pennicott L et al. AMPA receptor potentiators [Internet]. US11186567B2. 2021 [cited 2026 aug 13]. Available from: https:\/\/patents.google.com\/patent\/US11186567B2\/en?oq=US11186567B2"},{"key":"e_1_3_5_101_1","unstructured":"Gobbi G Gregorio DD. Administration of modulators of 5-ht and\/or ampa receptors for treating neurological conditions [internet]. WO2022023813A1. 2022 [cited 2026 aug 13]. Available from: https:\/\/patents.google.com\/patent\/WO2022023813A1\/en?oq=WO2022023813A1"},{"key":"e_1_3_5_102_1","unstructured":"Biogen. A randomized subject and Investigator blinded sponsor open placebo controlled 2 way crossover phase 1b study to examine the effects of PF-04958242 on ketamine induced cognitive impairment in healthy male volunteers [clinical trial registration] [internet]. Clinical trial registration no: NCT01749098. Available on: clinicaltrials.gov; 2019 [cited 2026 feb 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01749098"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.6"},{"key":"e_1_3_5_104_1","unstructured":"Biogen. A phase 2 randomized double-blind multiple-dose placebo-controlled study to evaluate the safety and efficacy of BIIB104 in subjects with cognitive impairment associated with schizophrenia (CIAS) [clinical trial registration] [internet]. Clinical trial registration no: NCT03745820. Available on: clinicaltrials.gov; 2023 [cited 2026 feb 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03745820"},{"key":"e_1_3_5_105_1","unstructured":"Antagonism of opioid-induced respiratory depression by CX1739 with preservation of opioid analgesia | clinical research trial listing [internet]. [cited 2026 feb 25]. Available from: https:\/\/www.centerwatch.com\/clinical-trials\/listings\/NCT02735629\/antagonism-of-opioid-induced-respiratory-depression-by-cx1739-with-preservation-of-opioid-analgesia\/antagonism-of-opioid-induced-respiratory-depression-by-cx1739-with-preservation-of-opioid-analgesia"},{"key":"e_1_3_5_106_1","unstructured":"Read 10 Min. RespireRx announces data for CX1739 clinical study in opioid induced respiratory depression. Available on BioSpace [Internet]. 2016 [cited 2026 feb 25]. Available from: https:\/\/www.biospace.com\/respirerx-announces-data-for-cx1739-clinical-study-in-opioid-induced-respiratory-depression"},{"key":"e_1_3_5_107_1","unstructured":"Mueller R Street LJ. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses [internet]. US20100173902A1. 2010 [cited 2026 aug 13]. Available from: https:\/\/patents.google.com\/patent\/US20100173902A1\/en?oq=US20100173902A1"},{"key":"e_1_3_5_108_1","unstructured":"Mueller R Street LJ. Bicyclic amide derivatives for the treatment of respiratory disorders [internet]. US8168632B2. 2012 [cited 2026 aug 13]. Available from: https:\/\/patents.google.com\/patent\/US8168632B2\/en?oq=US8168632B2"},{"key":"e_1_3_5_109_1","unstructured":"Institut de Recherches Internationales Servier. Efficacy and safety of 3 doses of S47445 versus placebo in patients with Alzheimer\u2019s disease at mild to moderate stages with depressive symptoms. A 24-week international multi-centre randomized double-blind placebo-controlled phase ii study in monotherapy followed by an optional 28-week extension period in Co-administration with donepezil. [clinical trial registration] [internet]. Clinical trial registration no: NCT02626572. Available on: clinicaltrials.gov; 2024 [cited 2026 feb 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02626572"},{"key":"e_1_3_5_110_1","unstructured":"Cordi A Desos P Lestage P et al. Derives dihydrobenzoxathiazepines leur preparation compositions pharmaceutiques et utilisation en tant que modulateurs des recepteurs ampa [Internet]. WO2012035216A1. 2012 [cited 2026 aug 13]. Available from: https:\/\/patents.google.com\/patent\/WO2012035216A1\/en?oq=WO2012%2f035216"},{"key":"e_1_3_5_111_1","unstructured":"Institut de Recherches Internationales Servier. Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major depressive disorder in patients with an inadequate response to antidepressant therapy: a randomised double-blind placebo controlled international multicentre study [clinical trial registration] [internet]. Clinical trial registration no: NCT02805439. Available on: clinicaltrials.gov; 2020 [cited 2026 feb 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02805439"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301444"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.15.4"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755\u20135949.2009.00088.x"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2021.173289"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/1873\u20133468.14824"},{"key":"e_1_3_5_117_1","unstructured":"Bank RPD. RCSB PDB - 8I0B: the crystal structure of human glutamate receptor 2 in complex with LT-102 [internet]. [cited 2026 feb 26]. Available from: https:\/\/www.rcsb.org\/structure\/8I0B"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00300"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2748595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2748595","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2748595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:18:22Z","timestamp":1792567102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2748595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":116,"alternative-id":["10.1080\/13543776.2026.2748595"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2748595","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}